Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19122772 | 0.76 | CYP19A1 (0.37) | KMT2ASCN4AKEAP1JMJD6CYP19A1 | |
| SCHEMBL23006749 | 0.76 | — | — | |
| SCHEMBL17662620 | 0.75 | GABRP (0.36) | KMT2ASCN4AKEAP1JMJD6CYP19A1 | |
| SCHEMBL19122410 | 0.75 | KMT2A (0.33) | KMT2ASCN4AKEAP1JMJD6 | |
| SCHEMBL16825528 | 0.75 | KCNH2 (0.41) | KMT2AKCNH2JMJD6PDE10A | |
| SCHEMBL19121617 | 0.75 | KMT2A (0.33) | KMT2ASCN4AKEAP1JMJD6 | |
| SCHEMBL17662619 | 0.75 | GABRP (0.36) | KMT2ASCN4AKEAP1JMJD6CYP19A1 | |
| SCHEMBL19122039 | 0.72 | CYP19A1 (0.37) | KMT2AKEAP1JMJD6CYP19A1 | |
| SCHEMBL19121576 | 0.72 | CYP19A1 (0.34) | KMT2AKEAP1JMJD6CYP19A1 | |
| SCHEMBL16825368 | 0.72 | ALOX15 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874466-B | N-substituted dioxocyclobutylamino-3-hydroxy-pyridinecarboxamides as CCR6 inhibitors | PFIZER INC. (US) | 2026-05-26 | — | — | CN | disclosed |
| US-20250333414-A1 | HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2025-10-30 | — | — | US | disclosed |
| CN-116874466-A | N-substituted dioxocyclobutylamino-3-hydroxy-pyridinecarboxamides as CCR6 inhibitors | 辉瑞公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-112672791-B | N-substituted dioxocyclobutylamino-3-hydroxy-pyridinecarboxamides as CCR6 inhibitors | 辉瑞公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2004035563-A1 | 3-HETEROCYCLYLPYRIDINE DERIVATIVES USEFUL AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333414-A1 | HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | STING1, MAVS, TBK1 | KMT2A 3850/4885SCN4A 3432/4885GRIN2B 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.